AstraZeneca’s mid-stage oral cholesterol drug is moving forward with Phase 3 trials, despite being behind rival Merck’s competitor in terms of clinical development progress. The company aims to generate over $5 billion in sales from the treatment if it reaches peak effectiveness. Positive test results have fueled optimism about its potential success, but concerns remain about whether it will surpass other options on the market.
Source: https://endpts.com/astrazenecas-cholesterol-pill-is-set-for-phase-3-but-lags-behind-merck-rival